Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis

Peginterferon beta‐1a reduced annualized relapse rate as compared with placebo and was approved to treat multiple sclerosis patients. A population pharmacokinetic and an exposure‐efficacy model were developed to establish the quantitative relationship between pharmacokinetics and annualized relapse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Clin Pharmacol
Hauptverfasser: Hu, Xiao, Hang, Yaming, Cui, Yue, Zhang, Jie, Liu, Shifang, Seddighzadeh, Ali, Deykin, Aaron, Nestorov, Ivan
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Pharmacometrics
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5516189/
https://ncbi.nlm.nih.gov/pubmed/28394418
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.883
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge